AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the most promising penny stocks under $5 to buy. On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a major transition into a clinical-stage biotechnology company. The firm ended the year with $75 million in total revenue, which was composed of $27 million from partnered programs and $48 million from licensing and royalties, while reporting a net loss of $146 million.

This loss reflects a significant pivot toward internal pipeline development, as evidenced by a $187 million investment in R&D. The company’s clinical pipeline saw substantial progress in 2025, highlighted by the advancement of its lead program, ABCL635, into Phase 2 studies for vasomotor symptoms/VMS. Encouraging target engagement data has notably increased the estimated probability of success for this program, with a major readout expected in the third quarter of 2026.

Additionally, the company’s second lead program, ABCL575, is currently in Phase 1 trials with data anticipated by year-end. To support this expanding portfolio, AbCellera has nearly completed its own clinical manufacturing facility, providing greater control over its supply chain and proprietary technology. While AbCellera Biologics Inc. (NASDAQ:ABCL) is reducing transparency on partner-initiated program starts by moving to less frequent reporting, it remains focused on internal first-in-class programs in oncology and immunology.

AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US.